Coherus Oncology (CHRS) Return on Capital Employed (2014 - 2026)

Coherus Oncology has disclosed Return on Capital Employed across 13 years of filings, most recently posting 22.47% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 22.47%, up 9210.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.47% (up 9210.0% YoY), and the FY2025 annual result was 18.05%, up 5991.0% from the prior year.
• Return on Capital Employed came in at 22.47% for Q1 2026 at Coherus Oncology, down from 15.57% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 15.57% in Q4 2025 to a low of 170.91% in Q3 2025.
• The 5-year median for Return on Capital Employed is 75.82% (2024), against an average of 80.02%.
• Across the five-year window, Return on Capital Employed sank 9509 bps in 2025 and jumped 9210 bps in 2026, its largest moves.
• Coherus Oncology's Return on Capital Employed stood at 68.1% in 2022, then decreased by 9 bps to 73.91% in 2023, then plunged by 39 bps to 103.03% in 2024, then surged by 85 bps to 15.57% in 2025, then slumped by 44 bps to 22.47% in 2026.
• The last three Return on Capital Employed figures came in at 22.47% (Q1 2026), 15.57% (Q4 2025), and 170.91% (Q3 2025), per Business Quant data.